Children's Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)...

Children's Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse
CO-Oximetry(TM) Technology
Pioneering Noninvasive and Continuous Hemoglobin Hospital-wide, Children's
Hospital Oakland Leverages State-of-the-Art Masimo Rainbow Platform to Advance
Pediatric Care

IRVINE, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the
inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that Children's Hospital & Research Center
Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse
CO-Oximetry technology. Standardizing to Masimo Rainbow SET makes Children's
Hospital Oakland the first children's hospital to pioneer new continuous
noninvasive blood monitoring capabilities hospital-wide--allowing earlier and
better clinical decisions without the intermittent pain and wait associated
with drawing blood.

By converting to Masimo Rainbow SET, Children's Hospital Oakland clinicians
will gain all the benefits and Measure-Through Motion capabilities of Masimo
SET pulse oximetry, along with the breakthrough innovation of the first-ever
continuous and noninvasive hemoglobin monitoring (SpHb(TM)) technology.
Noninvasive hemoglobin will allow clinicians at Children's to detect and treat
chronic or acute anemia earlier, identify internal bleeding sooner, and more
effectively manage blood transfusions for their patients. The ability to
immediately detect and treat potentially life-threatening conditions earlier
may help save lives and improve patient outcomes.

Katie Sabato, MS, RRT, director of Respiratory Care, Pulmonary Function &
Sleep Labs at Children's Hospital Oakland, stated, "All of our efforts are
focused on helping kids get better, which requires a very special level of
care and some of the world's most sophisticated technology. Masimo Rainbow SET
will allow us to measure critical components of a child's blood quickly and
easily, without the pain of a needle stick and the discomfort of having blood
drawn. It's also a great example of how we leverage advanced technology and
innovative care solutions to improve comfort and care and speed-up a child's
recovery."

Masimo Founder and CEO, Joe E. Kiani, stated, "We are proud of our
relationship with Children's Hospital Oakland. Children's was one of the first
children's hospitals to convert to Masimo SET years ago and, with a history of
leadership in the practice of neonatal and pediatric care, they are continuing
to lead new efforts to transform pediatric patient care with their conversion
to Masimo Rainbow SET Pulse CO-Oximetry. We are delighted that they have
chosen to significantly impact the care and treatment of children and advance
the practice of medicine using our noninvasive and continuous Rainbow
platform."

Masimo Rainbow SpHb is transforming the way patients are managed in the
operating room, intensive care unit and emergency department, where clinicians
are reporting earlier identification of necessary blood transfusions,
reduction in unnecessary transfusions and invasive tests, increased patient
safety, and improved clinical outcomes.

Amit Gupta, M.D., pediatric anesthesiologist at Children's Hospital & Research
Center Oakland, stated, "Preserving safe hemoglobin levels are always a
particular concern for pediatric patients who already have very little
hemoglobin to spare. With Masimo Rainbow SET in the peri-operative setting we
can noninvasively detect internal bleeding, fluid responsiveness, oxygen
saturation, pulse rate, and perfusion--all in a matter of seconds. Having
this level of physiological detail immediately available at our fingertips is
a tremendous benefit that helps to speed patient assessment, treatment, care,
and the safe return to optimal health."

Children's Hospital & Research Center Oakland is a regional and global
resource for advanced pediatric care, research and medical education. With
more than 200,000 patient visits per year, Children's has Northern
California's most active pediatric trauma center, the region's busiest
pediatric intensive care unit, and one of the largest sickle cell treatment
and research centers in the world.

About Children's Hospital & Research Center Oakland
Children's Hospital & Research Center Oakland is Northern California's only
freestanding and independent children's hospital. Children's is a leader in
many pediatric specialties including neonatology, cardiology, neurosurgery and
intensive care. The hospital is a designated Level 1 pediatric trauma center
and has the largest pediatric critical care facility in the region. Children's
Hospital has 190 licensed beds, 201 hospital-based physicians in 30
specialties, more than 2,600 employees and an annual operating budget of $312
million. Children's research arm, Children's Hospital Oakland Research
Institute (CHORI), is internationally renowned for taking state-of-the-art
basic and clinical research to the bedside with interventions for treating and
preventing human disease. CHORI has 300 staffers, a budget of about $50
million, and is ranked among the nation's top 10 research centers in National
Institutes of Health funding to children's hospitals. CHORI is a leader in
translational research, developing new vaccines for infectious diseases, and
discovering new treatment protocols for previously fatal or debilitating
conditions including cancer, sickle cell anemia, thalassemia, diabetes,
asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects,
hemophilia and cystic fibrosis. For more information, go to
www.childrenshospitaloakland.org.

About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements
This press release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, in connection with the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on current expectations
about future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our control
and could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various risk
factors, including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results, risks related to our belief
that Masimo Rainbow SET will provide sufficient sensitivity and specificity to
detect physiological abnormalities in real-time, enabling clinicians to detect
and identify potentially life-threatening conditions earlier and make better
clinical and treatment decisions for their patients, as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed with
the Securities and Exchange Commission ("SEC"), which may be obtained for free
at the SEC's website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their entirety by
the foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of today's
date. We do not undertake any obligation to update, amend or clarify these
forward-looking statements or the "Risk Factors" contained in our most recent
reports filed with the SEC, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.

Media Contacts:
Dana Banks
Masimo Corporation
+1 (949) 297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,
Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation.

SOURCE Masimo Corporation

Dana Banks of Masimo Corporation, +1-949-297-7348